Organisation paid for research Program year 2025 Source: CMS Open Payments

Arcare

Neither a doctor nor a teaching hospital

Research payments

$90,254

13 payments

Through program year 2025, Arcare is reported as receiving $90,254 in research payments, across 13 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$20	1
2024	Research	$25,632	2
2023	Research	$40,539	3
2021	Research	$1,238	3
2020	Research	$22,825	4

Breakdown

Who paid Research payments · program years 2020–2025

Novartis Pharmaceuticals Corporation $66,191 6 payments
Allergan Inc. $23,090 5 payments
Boehringer Ingelheim RCV GmbH & Co KG $973 2 payments

Studies the money was for Research payments · program years 2020–2025

Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $38,943 4 payments
A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy to usual care on LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (70 mg/dL) despite receiving maximally tolerated statin therapy (VICTORION-INITIATE) $27,248 2 payments
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $22,825 4 payments
POCC in NASH $973 2 payments
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $265 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.